Table 1: Demographic data and duration for admission and treatment vs. flow cytometry.
|
Variable number (%) |
Diagnosis |
|
|
|
|
|
B-ALL |
T-ALL |
Burkitt-ALL |
Others |
|
Gender 43 (84%) |
|
|
|
|
|
Male |
17 (65%) |
11 (85%) |
1 (50%) |
1 (50%) |
|
Female |
9 (35%) |
2 (15%) |
1 (50%) |
1 (50%) |
|
Age 43 (84%) |
|
|
|
|
|
Mean in years (SD) |
30.42 (14.5) |
24.85 (10) |
20 (1.4) |
21 (7.1) |
|
Median in years (IQR) |
27 (27) |
20 (16) |
20 |
21 |
|
Duration between first symptom and admission 43 (84%) |
|
|
|
|
|
Mean in days (SD) |
40.23 (50.7) |
27.85 (26.8) |
8.5 (2.1) |
18.5 (16.3) |
|
Median in days (IQR) |
25.5 (50) |
14 (38) |
8.5 |
18.5 |
|
Duration between admission and start of induction chemotherapy 43 (84%) |
|
|
|
|
|
Mean in days (SD) |
6.96 (6.3) |
5.69 (6.7) |
3 (1.4) |
4 (1.4) |
|
Median in days (IQR) |
6 (3) |
3(5) |
3 |
4 |
Others: Burkitt ALL and Biphenotypic ALL